Tissue | Expression Dynamics | Abbreviation |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/SEC14L1_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/SEC14L1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/SEC14L1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/SEC14L1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/SEC14L1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/SEC14L1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003052210 | Endometrium | AEH | intracellular receptor signaling pathway | 60/2100 | 265/18723 | 7.16e-08 | 3.77e-06 | 60 |
GO:00395293 | Endometrium | AEH | RIG-I signaling pathway | 11/2100 | 27/18723 | 8.09e-05 | 1.21e-03 | 11 |
GO:00395353 | Endometrium | AEH | regulation of RIG-I signaling pathway | 9/2100 | 20/18723 | 1.46e-04 | 1.94e-03 | 9 |
GO:00027535 | Endometrium | AEH | cytoplasmic pattern recognition receptor signaling pathway | 17/2100 | 60/18723 | 2.25e-04 | 2.75e-03 | 17 |
GO:00096159 | Endometrium | AEH | response to virus | 63/2100 | 367/18723 | 3.81e-04 | 4.10e-03 | 63 |
GO:00027645 | Endometrium | AEH | immune response-regulating signaling pathway | 76/2100 | 468/18723 | 5.76e-04 | 5.71e-03 | 76 |
GO:00395312 | Endometrium | AEH | regulation of viral-induced cytoplasmic pattern recognition receptor signaling pathway | 9/2100 | 24/18723 | 7.48e-04 | 7.12e-03 | 9 |
GO:00985864 | Endometrium | AEH | cellular response to virus | 20/2100 | 84/18723 | 8.14e-04 | 7.66e-03 | 20 |
GO:00395282 | Endometrium | AEH | cytoplasmic pattern recognition receptor signaling pathway in response to virus | 11/2100 | 34/18723 | 8.45e-04 | 7.82e-03 | 11 |
GO:00622074 | Endometrium | AEH | regulation of pattern recognition receptor signaling pathway | 23/2100 | 105/18723 | 1.19e-03 | 1.02e-02 | 23 |
GO:00026838 | Endometrium | AEH | negative regulation of immune system process | 69/2100 | 434/18723 | 1.76e-03 | 1.41e-02 | 69 |
GO:00022213 | Endometrium | AEH | pattern recognition receptor signaling pathway | 31/2100 | 172/18723 | 5.16e-03 | 3.23e-02 | 31 |
GO:003052215 | Endometrium | EEC | intracellular receptor signaling pathway | 65/2168 | 265/18723 | 2.52e-09 | 1.96e-07 | 65 |
GO:000275311 | Endometrium | EEC | cytoplasmic pattern recognition receptor signaling pathway | 20/2168 | 60/18723 | 7.27e-06 | 1.67e-04 | 20 |
GO:003952911 | Endometrium | EEC | RIG-I signaling pathway | 11/2168 | 27/18723 | 1.08e-04 | 1.49e-03 | 11 |
GO:000961513 | Endometrium | EEC | response to virus | 66/2168 | 367/18723 | 1.78e-04 | 2.20e-03 | 66 |
GO:003953511 | Endometrium | EEC | regulation of RIG-I signaling pathway | 9/2168 | 20/18723 | 1.87e-04 | 2.27e-03 | 9 |
GO:000276412 | Endometrium | EEC | immune response-regulating signaling pathway | 80/2168 | 468/18723 | 2.20e-04 | 2.64e-03 | 80 |
GO:003953111 | Endometrium | EEC | regulation of viral-induced cytoplasmic pattern recognition receptor signaling pathway | 9/2168 | 24/18723 | 9.45e-04 | 8.45e-03 | 9 |
GO:000268313 | Endometrium | EEC | negative regulation of immune system process | 72/2168 | 434/18723 | 1.04e-03 | 9.13e-03 | 72 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SEC14L1 | SNV | Missense_Mutation | | c.488N>C | p.Ile163Thr | p.I163T | Q92503 | protein_coding | deleterious(0) | probably_damaging(0.982) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SEC14L1 | SNV | Missense_Mutation | | c.841N>G | p.Leu281Val | p.L281V | Q92503 | protein_coding | deleterious(0.02) | possibly_damaging(0.858) | TCGA-C8-A1HM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | CR |
SEC14L1 | SNV | Missense_Mutation | novel | c.481N>A | p.Glu161Lys | p.E161K | Q92503 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
SEC14L1 | SNV | Missense_Mutation | novel | c.935N>G | p.Tyr312Cys | p.Y312C | Q92503 | protein_coding | tolerated(0.17) | benign(0.018) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
SEC14L1 | SNV | Missense_Mutation | rs773798440 | c.2026N>A | p.Gly676Ser | p.G676S | Q92503 | protein_coding | tolerated(0.57) | benign(0.003) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
SEC14L1 | SNV | Missense_Mutation | rs752687715 | c.1528N>A | p.Glu510Lys | p.E510K | Q92503 | protein_coding | tolerated(0.07) | possibly_damaging(0.738) | TCGA-EA-A3QE-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
SEC14L1 | SNV | Missense_Mutation | novel | c.2122N>T | p.His708Tyr | p.H708Y | Q92503 | protein_coding | tolerated(1) | benign(0.271) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
SEC14L1 | SNV | Missense_Mutation | novel | c.135N>G | p.Phe45Leu | p.F45L | Q92503 | protein_coding | tolerated(0.63) | benign(0.015) | TCGA-UC-A7PD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
SEC14L1 | SNV | Missense_Mutation | rs375335873 | c.2098N>A | p.Ala700Thr | p.A700T | Q92503 | protein_coding | tolerated(0.24) | benign(0.39) | TCGA-VS-A94Z-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
SEC14L1 | SNV | Missense_Mutation | novel | c.539N>A | p.Arg180His | p.R180H | Q92503 | protein_coding | deleterious(0.03) | probably_damaging(0.923) | TCGA-A6-3810-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |